Tempest Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPST research report →
About the company
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications.
- CEO
- Matthew Angel
- IPO
- 2012
- Employees
- 24
- HQ
- Brisbane, CA, US
Price Chart
- Market Cap
- $4.84M
- P/E
- -0.18
- P/S
- 0.00
- P/B
- 14.50
- EV/EBITDA
- -0.25
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -729.89%
- ROIC
- -499.76%
- Revenue
- $0 · 0.00%
- Net Income
- $-26,262,000 · 37.24%
- EPS
- $-6.33 · -322.00%
- Op Income
- $-26,575,000
- FCF YoY
- 19.85%
- 52W High
- $12.23
- 52W Low
- $1.02
- 50D MA
- $1.57
- 200D MA
- $4.05
- Beta
- -1.78
- Avg Volume
- 194.56K
Get TickerSpark's AI analysis on TPST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 24, 26 | Angel Matthew | buy | 231,482 |
| Mar 24, 26 | Angel Matthew | buy | 231,482 |
| Jun 4, 26 | Yee John D. | other | 25,000 |
| Jun 4, 26 | Yee John D. | other | 0 |
| Jun 4, 26 | Richey William Drake | other | 0 |
| Jun 4, 26 | Richey William Drake | other | 25,000 |
| Mar 31, 26 | Trojanowski Justin | other | 22,000 |
| Mar 31, 26 | Maestas Nicholas | other | 140,000 |
| Mar 24, 26 | Angel Matthew | buy | 231,482 |
| Feb 4, 26 | Angel Matthew | other | 269,621 |
Our TPST coverage
Recent articles, reports, and earnings notes.
No research on TPST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TPST report →Similar companies
Peers in the same neighborhood.